Shares of Cipla were trading 2% above on 27 October after the company announced its quarterly earnings for the July-September.

The Indian pharma major reported a 43.3% year-on-year (YoY) increase in its consolidated net profit at Rs 1,131 crore for the quarter under review against the Rs 789 crore reported in the year-ago quarter.

The company’s revenue saw a 14.6% YoY increase to Rs 6,678 crore against Rs 5,828.5 crore, marking its highest-ever quarterly revenue.

The company’s EBITDA (earnings before interest, taxes, depreciation and amortisation) was at Rs 1,734 crore for Q2, and the EBITDA margin was at 26% against 22.2% reported in the same quarter of the previous fiscal year.

Umang Vohra, MD & Global CEO of Cipla, said, “Pleased to share an exceptional set of results reflecting the strength of our core business across key markets of India, North America and South Africa. We reported our highest ever quarterly revenue with EBITDA margins scaling up to 26%.”

He added that the company has a pipeline of new products that are processing very well with key milestones in respiratory and Peptide assets and is focused on driving profitable growth across businesses.

The company’s branded prescriptions outpaced the market growth even though seasonal trends impacted the consumer business during the quarter.

At 3:30 pm, the shares of Cipla closed 2.19% above at Rs 1,176 on NSE.